Dishman Carbogen Amcis
DCAL · Pharma > Pharmaceuticals & Drugs · Chairman: Janmejay R Vyas · MD: Arpit J Vyas · Listing date: Sept. 22, 2017 · Employees: 929 · Ahmedabad · http://imdcal.com

Stock Price vs Company Growth
1d
1.8%
1w
6.3%
1m
24.4%
3m
18.3%
6m
16.2%
1y
15.3%
5y
9.0%
all
5.3%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 224 1.8%
223
321
Company Overview

Sales
2,759 Cr
Growth: 13.8%
Profit after Tax
134 Cr
Growth: 31.5%
Small Cap
3,520 Cr
P/E: 25.9x
Industry P/E: 33.3x
Fundamentals

Sales (Cr) ₹ 2,759
Growth 13.8%
EBITDA 21.1%
P/S 1.3x
Dividend 0.0%
P/E 25.9x
Book Value ₹ 378
PEG Ratio 1.9x
ROE 2.3%
P/B 0.6x
Shareholding Pattern

Institutions
L And T Mutual Fund Trustee Ltd-L And T Flexicap Fund
2.9 %
Mukul Agrawal
2.55 %
Government Pension Fund Global
2.33 %
Aditya Birla Sun Life Trustee Private Limited A/C Aditya Birla Sun Life Flexi Cap Fund
1.88 %
Hbm Healthcare Investment(Cayman) Ltd.
1.62 %
Promoters
Adimans Technologies Llp
59.32 %
Others
Increase    Decrease    No change
Company Profile Detailed

The company is a fully integrated CRAMS player working with global pharmaceutical innovators. It has a global presence with development and manufacturing facilities across Europe, India, and China. It provides end-to-end, integrated, high-value, niche CRAMS offering, right from process research & development to late-stage clinical and commercial manufacturing facilities along with the supply of Active Pharmaceutical Ingredients (API) to innovator pharmaceutical companies.
Investors (53)
Followers (1)